Population Pharmacokinetic Model of Pegbing in Healthy Subjects and Chronic Hepatitis B Patients
CPT: Pharmacometrics & Systems Pharmacology · 2025
DOI: 10.1002/psp4.70104 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Weizhe Jian und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Polyethylene Glycols, Antiviral Agents, Models, Biological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Pegbing (peginterferon alpha‐2b) is a polyethylene glycol‐modified interferon α‐2b injection that has demonstrated favorable efficacy and safety profiles in the treatment of chronic hepatitis B (CHB). This study aimed to develop a population pharmacokinetic (PopPK) model of Pegbing in both healthy subjects and CHB patients and to investigate the influence of covariates on its pharmacokinetic behavior. Pharmacokinetic data were obtained from a Phase I trial in healthy volunteers and a Phase II trial in CHB patients. A one‐compartment model with a target‐mediated drug disposition (TMDD) component incorporating IFN receptor downregulation was established to describe the pooled data from 28 healthy subjects and 39 CHB patients. Physiologically reasonable parameters were estimated, providing a good description and prediction of the model. Furthermore, the final PopPK model was externally validated using an independent dataset of 115 CHB patients. In the covariate analysis, health status (healthy v.s. CHB) was a significant covariate, affecting the Pegbing absorption rate, creatinine clearance was associated with clearance, and body weight affected the volume of distribution. Compared with healthy subjects, CHB patients exhibited a consistent area under the curve (AUC) but a higher C max . A PopPK model of Pegbing in both healthy volunteers and CHB patients was successfully established. Based on the model simulation, covariate‐based dose adjustment is unnecessary for CHB patients with normal renal function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, China.
- Xiamen Amoytop Biotech Co., LTD, Xiamen, China.
ORCID-Profile: Tianyan Zhou
Zitieren
APA
Jian, W., Yin, Y., Chen, R., Luo, P., Wang, T., Gu, J., Du, Z., Cai, L., Bao, T., Xue, J., He, R., & Zhou, T. (2025). Population Pharmacokinetic Model of Pegbing in Healthy Subjects and Chronic Hepatitis B Patients. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70104
Vancouver
Jian W, Yin Y, Chen R, Luo P, Wang T, Gu J, et al. Population Pharmacokinetic Model of Pegbing in Healthy Subjects and Chronic Hepatitis B Patients. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70104
BibTeX
@article{Jian2025,
author = {Jian, Weizhe and Yin, Yalin and Chen, Rong and Luo, Pingyao and Wang, Tianyu and Gu, Jianbo and Du, Zhengfang and Cai, Lei and Bao, Tianyu and Xue, Junsheng and He, Ruoyi and Zhou, Tianyan},
title = {Population Pharmacokinetic Model of Pegbing in Healthy Subjects and Chronic Hepatitis B Patients},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
doi = {10.1002/psp4.70104}
}
EUVIMED